Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Ionis Pharmaceuticals Slumped Today

By Brian Orelli, PhD - Apr 17, 2019 at 2:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Information from competitors and a collaborator sent the high-flying biotech lower.

What happened

Shares of Ionis Pharmaceuticals ( IONS -3.10% ) are down 13% at 12:45 p.m. EDT without any direct news from the biotech.

However, there were a couple of indirect news items from competitors and collaborators that seem to have investors taking profits on Ionis' shares that were up 87% over the last year through yesterday.

So what

First, Novartis ( NVS -0.61% ) announced interim phase 3 data for its gene therapy Zolgensma, which treats spinal muscular atrophy (SMA), the same disease treated by Ionis' and Biogen's ( BIIB -1.01% ) Spinraza. Biogen is only down 1%, but Spinraza sales contribute a smaller portion of Biogen's overall revenue than Spinraza royalties do for Ionis.

Of the seven treated infants with type 1 SMA that had reached 10.5 months or older, six of them were alive and not requiring permanent ventilation. There wasn't a control arm of untreated patients, but typically, 50% of babies do not survive or will require permanent ventilation by the time they reach 10.5 months of age. Novartis also released data on the infants' development milestones -- turning over or sitting unassisted, for example -- which appeared fairly similar to the positive phase 1 data.

The phase 3 study isn't scheduled to conclude until next year, but Novartis has already submitted marketing applications to regulators. The FDA is expected to make a decision next month, while decisions in the EU and Japan are expected later in the year. On the plus side for Ionis and Biogen, Zolgensma is likely to only be approved for type 1 SMA patients, while Spinraza is also approved for the less severe type 2 and type 3 SMA, so the immediate impact will be muted.

Hands examining an infants foot

Image source: Getty Images.

Roche also added fuel to the fire with positive comments on its SMA drug risdiplam, which can be used for all three types of SMA, on its first-quarter conference call. Management also noted that it wouldn't be presenting updated data for RG6042 at the American Academy of Neurology meeting next month; Roche licensed RG6042, which treats Huntington's disease, from Ionis, which will get royalties on sales if the drug is approved.

Now what

None of the news today seems like a major issue for Ionis. We've known about the competition for Spinraza, and no update on RG6042 doesn't mean Roche isn't moving the drug through the clinic as quickly as possible.

Nevertheless, it's understandable that any slightly negative news might cause investors to take some profits considering the sustained run Ionis' shares have been on over the last year. Long-term investors looking to pick up additional shares should consider the buying opportunity.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
$26.60 (-3.10%) $0.85
Novartis AG Stock Quote
Novartis AG
$79.78 (-0.61%) $0.49
Biogen Inc. Stock Quote
Biogen Inc.
$233.72 (-1.01%) $-2.39

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.